scholarly journals Secondary lymphoid tissue and costimulation‐blockade resistant rejection: A nonhuman primate renal transplant study

2019 ◽  
Vol 19 (8) ◽  
pp. 2350-2357 ◽  
Author(s):  
Michael S. Mulvihill ◽  
Kannan P. Samy ◽  
Qimeng A. Gao ◽  
Robin Schmitz ◽  
Robert P. Davis ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Nonhuman Primate ◽  
Lymphoid Tissue ◽  
Costimulation Blockade ◽  
Secondary Lymphoid Tissue

scholarly journals Blockade of Secondary Lymphoid Tissue Chemokine ExacerbatesPropionibacterium acnes-Induced Acute Lung Inflammation

2001 ◽  
Vol 166 (3) ◽  
pp. 2071-2079 ◽  
Author(s):  
Meiji Itakura ◽  
Atsuko Tokuda ◽  
Hiroshi Kimura ◽  
Shigenori Nagai ◽  
Hiroyuki Yoneyama ◽  
...  
Keyword(s):  
Lymphoid Tissue ◽  
Lung Inflammation ◽  
Acute Lung Inflammation ◽  
Secondary Lymphoid Tissue

scholarly journals Local Expression of Secondary Lymphoid Tissue Chemokine Delivered by Adeno-Associated Virus within the Tumor Bed Stimulates Strong Anti-Liver Tumor Immunity

2007 ◽  
Vol 81 (17) ◽  
pp. 9502-9511 ◽  
Author(s):  
Chun-min Liang ◽  
Cui-ping Zhong ◽  
Rui-xia Sun ◽  
Bin-bin Liu ◽  
Cheng Huang ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Lymphoid Tissue ◽  
Critical Role ◽  
Antitumor Immune Response ◽  
Target Cells ◽  
Lymphoid Tissues ◽  
Adeno Associated Virus ◽  
Secondary Lymphoid Tissue ◽  
Local Expression

ABSTRACT Development of an effective antitumor immune response depends on the appropriate interaction of effector and target cells. Thus, the expression of chemokines within the tumor may induce a more potent antitumor immune response. Secondary lymphoid tissue chemokine (SLC) is known to play a critical role in establishing a functional microenvironment in secondary lymphoid tissues. Its capacity to attract dendritic cells (DCs) and colocalize them with T cells makes it a good therapeutic candidate against cancer. In this study, we used SLC as a treatment for tumors established from a murine hepatocellular carcinoma model. SLC was encoded by recombinant adeno-associated virus (rAAV), a system chosen for the low host immunity and high efficiency of transduction, enabling long-term expression of the gene of interest. As a result, rAAV-SLC induced a significant delay of tumor progression, which was paralleled by a profound infiltration of DCs and activated CD4+ T cells and CD8+ T cells (CD3+ CD69+ cells) into the tumor site. In addition, rAAV-SLC treatment was also found to reduce tumor growth in nude mice, most likely due to inhibition of neoangiogenesis. In conclusion, local expression of SLC by rAAV represents a promising approach to induce immune-mediated regression of malignant tumors.

Sign in / Sign up

Export Citation Format

Share Document